Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder, mainly occurred in children. ADHD is firstly diagnosed in childhood and often last till adulthood. The most common symptoms of ADHD are children may daydream a lot, forget or loose things, children may have hard time resisting temptation, have trouble taking turns, have difficulty getting along with others, children are overly active, and have trouble paying attention. Attention deficit hyperactivity disorder (ADHD) is treated with stimulant and non-stimulant drugs.

The global attention deficit hyperactivity disorder (ADHD) therapeutics market is estimated to be valued at US$ 18,169.0 million in 2020 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2020-2027).

Figure 1. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Value (US$ Mn), 2016-2027

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics  | Coherent Market Insights

Increasing prevalence of attention deficit hyperactivity disorder is expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period. For instance, according to the study titled ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups’ published in the JAMA Network Open in November 2019, the prevalence of attention deficit hyperactivity disorder in adults among 7 racial and ethnic groups increased from 0.43% in 2007 to 0.96% in 2016.

Furthermore, key companies focusing on research and development in the treatment of attention deficit hyperactivity disorder are expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a U.S. subsidiary, announced positive top-line results from phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.

request-sample

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 18,169.0 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.1% 2027 Value Projection: US$ 29,365.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type:
    • Stimulants: Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate.
    • Non-stimulants: Atomoxetine, Bupropion, Guanfacine, Clonidine.
  • By Age Group: Pediatric and Adolescent, Adult.
  • By Distribution Channel: Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, E-commerce.
Companies covered:

Amneal Pharmaceuticals, Inc, Eli Lilly And Company, Janssen Pharmaceuticals, Inc, Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, and Purdue Pharma L.P.

Growth Drivers:
  • Increasing prevalence of attention deficit hyperactivity disorder (ADHD)
  • Increasing clinical trials by key players and academic institutes
Restraints & Challenges:
  • Adoption and launch of alternative treatment methods
  • Drug abuse and contraindications & side-effects associated with ADHD drugs

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 60.3 million infected individuals worldwide as of 26th November, 2020.

Furthermore, due to COVID-19 pandemic, the governments of various countries are taking initiatives to combat attention deficit hyperactivity disorder (ADHD) in children during the COVID-19 pandemic. For instance, according to the study published in the child and adolescent health, in THE LANCET journal, on April 17, 2020, it was found that during COVID-19 pandemic, the patients suffering from attention deficit hyperactivity disorder (ADHD) have become more vulnerable due to the stress caused by the pandemic.

Figure 2. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (%), By Region, 2020

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics  | Coherent Market Insights

North America is expected to hold dominant position in the global attention deficit hyperactivity disorder therapeutics market during the forecast period, owing to launch of products by players in the region. For instance, in March 2019, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received the U.S. Food and Drug Administration (FDA) approval for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged six years and older.

Key Players

Major players operating in the global attention deficit hyperactivity disorder (ADHD) therapeutics market include Amneal Pharmaceuticals, Inc, Eli Lilly And Company, Janssen Pharmaceuticals, Inc, Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, and Purdue Pharma L.P.

The global attention deficit hyperactivity disorder (ADHD) therapeutics market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, and Combined Presentation and various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight.

Market Dynamics

Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Akili Interactive Labs, a digital medicine  prescription company in the U.S., received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is a captivating video game experience to improve attention in children suffering from ADHD.

Key features of the study:

  • This report studies the current scenario as well as the future potential of the global attention deficit hyperactivity disorder therapeutics market. The market for attention deficit hyperactivity disorder therapeutics is segmented on basis of drug type, age group, distribution channel, and region.
  • This report provides in-depth analysis of the global attention deficit hyperactivity disorder therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020–2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
  • It profiles leading players in the global attention deficit hyperactivity disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
  • The global attention deficit hyperactivity disorder therapeutics market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder therapeutics market

Detailed Segmentation:

  • Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Drug Type:
    • Stimulants
      • Amphetamine
      • Methylphenidate
      • Dextroamphetamine
      • Dexmethylphenidate
      • Lisdexamfetamine Dimesylate
    • Non-stimulants
      • Atomoxetine
      • Bupropion
      • Guanfacine
      • Clonidine
  • Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Age Group:
    • Pediatric and Adolescent
    • Adult
  • Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Distribution Channel :
    • Specialty Clinics
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-commerce
  • Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Region:
    • North America
      • By Drug Type:
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group :
        • Pediatric and Adolescent
        • Adult
      • By Distribution Channel :
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group :
        • Pediatric and Adolescent
        • Adult
      • By Distribution Channel :
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group :
        • Pediatric and Adolescent
        • Adult
      • By Distribution Channel :
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group :
        • Pediatric and Adolescent
        • Adult
      • By Distribution Channel :
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group :
        • Pediatric and Adolescent
        • Adult
      • By Distribution Channel :
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group :
        • Pediatric and Adolescent
        • Adult
      • By Distribution Channel :
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Amneal Pharmaceuticals, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Eli Lilly And Company
    • Janssen Pharmaceuticals, Inc.
    • Noven Pharmaceuticals, Inc.
    • RespireRx Pharmaceuticals Inc.
    • Otsuka Pharmaceutical Co., Ltd
    • Neos Therapeutics, Inc.
    • American Brivision (Holding) Corporation
    • Novartis International AG
    • Takeda Pharmaceutical Company Limited
    • GlaxoSmithKline plc
    • Purdue Pharma L.P.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Age Group
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Value Chain Analysis.
  4. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Impact of COVID-19 Pandemic
    • COVID19 Epidemiology
    • Government Initiatives to Combat Attention Deficit Hyperactivity Disorder (ADHD) amid COVID-19
  5. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        •  Stimulants
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Amphetamine
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Methylphenidate
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Dextroamphetamine
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Dexmethylphenidate
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Lisdexamfetamine Dimesylate
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Non-stimulants
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Atomoxetine
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Bupropion
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Guanfacine
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Clonidine
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Age Group, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Pediatric and Adolescent
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Adult
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Distribution Channel, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Specialty Clinics
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • E-commerce
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Age Group, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Age Group, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Age Group, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Age Group, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Age Group, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Age Group, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Amneal Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly And Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Janssen Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Noven Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RespireRx Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Otsuka Pharmaceutical Co., Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Neos Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • American Brivision (Holding) Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Purdue Pharma L.P.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 35 market data tables and 38 figures on " Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Global forecast to 2027”.

Frequently Asked Questions

The global attention deficit hyperactivity disorder (ADHD) therapeutics market size is estimated to be valued at US$ 18,169.0 million in 2020 and is expected to exhibit a CAGR of 7.1 % between 2020 and 2027.
Increasing prevalence of attention deficit hyperactivity disorder (ADHD) and increasing clinical trials by key players and academic institutes are driving growth of the global attention deficit hyperactivity disorder (ADHD) therapeutics market.
Stimulants segment is estimated to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to an increasing number of launch of new products for the treatment of patients with ADHD by key companies.
Adults segment is estimated to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to increasing prevalence of attention deficit hyperactivity disorder (ADHD) in adult population, globally.
Retail pharmacies segment is estimated to hold major market share in the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period, owing to increasing number of retail pharmacies & chain stores, easy access of products, and strategic tie-ups between major companies & retail pharmacies.
North America is estimated to generate largest revenue share in 2020 in the global attention deficit hyperactivity disorder (ADHD) therapeutics market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner